There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), Exelixis (EXEL – Research Report) and Impedimed Limited (IPDQF – Research Report) with bullish sentiments.
Eli Lilly & Co (LLY)
In a report released today, Carter Gould from Barclays maintained a Buy rating on Eli Lilly & Co, with a price target of $810.00. The company’s shares closed last Tuesday at $705.03, close to its 52-week high of $742.00.
According to TipRanks.com, Gould is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $715.69 average price target, representing a -3.5% downside. In a report issued on January 23, Cantor Fitzgerald also maintained a Buy rating on the stock with a $630.00 price target.
See today’s best-performing stocks on TipRanks >>
Exelixis (EXEL)
Barclays analyst Peter Lawson maintained a Buy rating on Exelixis yesterday and set a price target of $25.00. The company’s shares closed last Tuesday at $21.83.
According to TipRanks.com, Lawson is a 4-star analyst with an average return of
Currently, the analyst consensus on Exelixis is a Strong Buy with an average price target of $26.87, which is a 25.8% upside from current levels. In a report issued on January 25, Jefferies also maintained a Buy rating on the stock with a $30.00 price target.
Impedimed Limited (IPDQF)
In a report issued on February 2, Shane Storey from Wilsons maintained a Buy rating on Impedimed Limited, with a price target of A$0.20. The company’s shares closed last Monday at $0.07.
According to TipRanks.com, Storey is a 3-star analyst with an average return of
Currently, the analyst consensus on Impedimed Limited is a Moderate Buy with an average price target of $0.13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LLY:
- Eli Lilly (NYSE:LLY) Gains after Strong Q4 Results
- Options Volatility and Implied Earnings Moves Today, February 06, 2024
- Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
- Notable companies reporting before tomorrow’s open
- Eli Lilly Stock: All Eyes on Earnings This Week — Here’s What J.P. Morgan Expects
